tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
PremiumCompany AnnouncementsGenelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
2M ago
Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum
Premium
Ratings
Genelux Corp: Strong Buy Rating Backed by Promising Olvi-Vec Developments and Sector Momentum
2M ago
Genelux price target raised to $20 from $10 at Maxim
Premium
The Fly
Genelux price target raised to $20 from $10 at Maxim
2M ago
Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments
PremiumRatingsPromising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments
4M ago
Genelux reports Q2 EPS (20c), consensus (22c)
Premium
The Fly
Genelux reports Q2 EPS (20c), consensus (22c)
4M ago
Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy
Premium
Ratings
Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy
5M ago
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating
PremiumRatingsPromising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating
8M ago
Genelux reports Q1 EPS (21c), consensus (24c)
Premium
The Fly
Genelux reports Q1 EPS (21c), consensus (24c)
8M ago
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements
Premium
Ratings
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100